Ensaios clínicos de Melanoma em Ohio
40 estudos para Melanoma estão buscando participantes em locais em Ohio.
Cidades em Ohio
- Columbus21 estudos
- Cincinnati17 estudos
- Cleveland13 estudos
- Toledo8 estudos
- Akron8 estudos
- Dayton7 estudos
- Findlay3 estudos
- Youngstown3 estudos
- Newark3 estudos
- Parma3 estudos
Texto oficial do estudo (Inglês)
DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Miami Valley Hospital South, Centerville
- Premier Blood and Cancer Center, Dayton
- Miami Valley Hospital North, Dayton
- e mais 2
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Oncology Hematology Care Clinical Trials, Cincinnati
- Seidman Cancer Center, Cleveland
- The Ohio State University Wexner Medical Center, Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06246916A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
RecrutandoFase 2
Até 25 anos · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07621614Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Oncology Hematology Care, Cincinnati
- Ohio State University, Columbus
RecrutandoFase 3
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05727904Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Good Samaritan Hospital - Cincinnati, Cincinnati
- e mais 5
RecrutandoFase 3
Idades 75 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07068074Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Ohio State University, Columbus
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT06529822A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- e mais 56
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Cincinnati Medical Center, Cincinnati
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07287917A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Cleveland Clinic Taussig Cancer Center, Cleveland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07070232Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- e mais 44
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT05334069A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Cleveland Clinic, Cleveland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT04913285Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- e mais 5
RecrutandoEstudo observacional
Até 25 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- University of Cincinnati Cancer Center, Cincinnati
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT05592626Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1
Idades de 18 a 99 · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT04697576Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de jun. de 2026 · NCT05588453A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Cincinnati, Cincinnati
RecrutandoFase 1/2
Idades de 18 a 70 · Todos os sexos · Atualizado em 11 de jun. de 2026 · NCT05361174Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- University of Cincinnati Cancer Center, Cincinnati
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de jun. de 2026 · NCT03947385Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Christ Hospital Cancer Center, Cincinnati
- Taylor Cancer Research Center, Maumee
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de mai. de 2026 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mai. de 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Cole Eye Institute-9500 Euclid Ave, Cleveland
- Ohio State Eye and Ear Institute, Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The Ohio State University, Columbus
RecrutandoFase 2/3
Todas as idades · Todos os sexos · Atualizado em 2 de abr. de 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- Dayton Physician LLC - Englewood, Dayton
- e mais 9
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 2
Idades de 18 a 99 · Todos os sexos · Atualizado em 10 de mar. de 2026 · NCT06223659Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Todas as idades · Todos os sexos · Atualizado em 9 de mar. de 2026 · NCT04792463Promoting Immunotherapy Efficacy With Low-Dose Liver RT
- University of Cincinnati Medical Center, Cincinnati
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 27 de fev. de 2026 · NCT07225036Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- The Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de fev. de 2026 · NCT05549297A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Todas as idades · Todos os sexos · Atualizado em 17 de fev. de 2026 · NCT04567706Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Ohio State University Wexner Medical Center, Columbus
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de dez. de 2025 · NCT03567889A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de nov. de 2025 · NCT05914116Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de out. de 2025 · NCT06249048SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic, Cleveland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mai. de 2025 · NCT05970497Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- University Hospitals Avon Health Center, Avon
- Miami Valley Hospital South, Centerville
- University Hospitals Geauga Medical Center, Chardon
- e mais 6
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 27 de nov. de 2024 · NCT03860883A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de nov. de 2024 · NCT05824975Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.